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Introduction
Systemic juvenile idiopathic arthritis (sjia) is a chronic
inflammatory disease characterized by prolonged sys-
temic and synovial inflammation. Life-threatening com-
plication of sjia is the macrophage activation syndrome
(MAS). Tocilizumab (TCZ) is highly effective in children
with sjia. However, MAS remains under the treatment
of TCZ.
Objectives
To assess features of sjia developed macrophage activa-
tion syndrome during the course of TCZ therapy.
Methods
122 patients (aged 1-17 years) with sjia received TCZ at
the dose of 8 or 12 mg/kg every 2 or 4 weeks in Scienti-
fic Center of Children Health. Three patients (1 male-10
years, 2 females-7 and 1.9 years old) developed MAS
during the course of TCZ treatment. In these patients,
clinical features and laboratory findings were evaluated
and compared with diagnostic guidelines.
Results
The disease duration before initial infusion of TCZ was 8,
5,5 and 0,9 years. Two of them had history of MAS and
developed MAS after first infusion of TCZ. One patient
received corticosteroids at the onset of MAS - was 0.1 mg/
kg. The diagnostic clinical criteria of MAS complicating
sjia such as central nervous system dysfunction, hemor-
rhage were rarely observed. Furthermore, high fever
was not seen at the onset of MAS in one patient. The
laboratory criteria such as decreased platelet count,
elevated levels of aspartate aminotransferase, LDH,
decreased white blood cell count, and hypofibrinogenemia,
hyperferritinemia were fulfilled in these patients. Addition-
ally, ferritinemia was commonly observed in early phase of
MAS. Since hyperferritinemia is hardly observed even in
active s-JIA during TCZ treatment, it was useful to have
early suspicion of MAS. However, one of the patients had
normal level of CRP. One of them depeloped hepatitis
with hyperbilirubinemia and high level of AST, ALT. After
the diagnosis of MAS was established, infusion of
metylprednisolone and prednisolone treatment per os (1-2
mg/kg/day) were immediately started, and the patients
responded favorably to these treatments. The TCZ
treatment was discontinued in two patients.
Conclusion
MAS would occur unexpectedly despite no apparent
trigger and few clinical symptoms during the course of
TCZ. Blockade of IL-6 alone would not be sufficient to
avoid occurrence of MAS. We should have early suspi-
cion of MAS in case with thrombocytopenia and
hyperferritinemia despite subtle clinical symptoms.
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